Pfizer Inc. (NYSE:PFE) said Monday that its first-quarter profit dropped 15% despite sharp cost cutting. The earnings decline reflected cheaper generic competition that continues to reduce sales of its multiple medicines and the end of some partnerships with other drug makers.Pfizer Inc. (NYSE:PFE) shares after opening at $30.26 moved to $30.27 on last trade day and at the end of the day closed at $29.96. Company price to sales ratio in past twelve months was calculated as 3.71 and price to cash ratio as 5.90. Pfizer Inc. (NYSE:PFE) showed a negative weekly performance of -6.49%.
Merck & Co., Inc. (NYSE:MRK) announced that it has entered into a definitive agreement to sell its Merck Consumer Care (MCC) business to Bayer AG (BAYRY) for $14.2 billion. Under the terms of the agreement, Bayer AG will acquire Merck’s existing OTC business, including the global trademark and prescription rights for Claritin® and Afrin®.Merck & Co., Inc. (NYSE:MRK) shares advanced 0.70% in last trading session and ended the day on $58.63. MRK return on equity ratio is recorded as 12.40%and its return on assets is 5.70%. Merck & Co., Inc. (NYSE:MRK) yearly performance is 32.95%.
Bristol-Myers Squibb Company (NYSE:BMY) announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (mRCC) will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 30-June 3. Bristol-Myers Squibb Co (NYSE:BMY) shares moved up 0.46% in last trading session and was closed at $50.03, while trading in range of $49.17 – $50.07. Bristol-Myers Squibb Co (NYSE:BMY) year to date (YTD) performance is -5.21%.
AstraZeneca Plc (ADR) (NYSE:AZN) has won US approval for Epanova, a new pill for heart disease, providing a welcome but relatively minor piece of good news as it fights a $106 billion takeover approach from Pfizer Inc. AstraZeneca plc (ADR) (NYSE:AZN) weekly performance is 3.71%. On last trading day company shares ended up $79.87. AstraZeneca plc (ADR) (NYSE:AZN) distance from 50-day simple moving average (SMA50) is 19.02%. Analysts mean target price for the company is $76.67.
Johnson & Johnson (NYSE:JNJ) suspended worldwide sales of its device used in fibroid surgery amid concerns over its potential to spread undetected cancer beyond the uterus. The company said it was suspending the sale of its power morcellators until their role in fibroid treatment is better understood and redefined by the medical community.Johnson & Johnson (NYSE:JNJ) shares after opening at $99.29 moved to $100.17 on last trade day and at the end of the day closed at $100.00. Company price to sales ratio in past twelve months was calculated as 3.93 and price to cash ratio as 9.68. Johnson & Johnson (NYSE:JNJ) showed a negative weekly performance of -1.32%.
Leave a Reply